蛋白激酶C三角酶增强了肝细胞癌的诊断性能
Chika Nakagawa1, Tsunekazu Oikawa1, Kohji Yamada2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
概括
蛋白激酶C三角酶 (PKCδ) 显示为早期肝细胞癌 (HCC) 检测的新生物标志物具有前途. 这种生物标志物克服了像AFP和DCP这样的传统标志物的局限性,在不同患者群体中提供了高灵敏度和特异性.
科学领域:
- 肝细胞癌研究 肝细胞癌研究
- 生物标志物发现发现
- 瘤学 诊断 诊断 瘤学
背景情况:
- 肝细胞癌 (HCC) 的常规生物标志物,包括α-fetoprotein (AFP) 和des-gamma-carboxy prothrombin (DCP),具有显著的局限性.
- 这些限制包括早期HCC的低敏感性和肝损伤,非病毒性HCC和华法林使用的低特异性.
- 对于新的生物标志物来改善HCC检测和克服现有方法的缺陷,这是非常必要的.
研究的目的:
- 评估血清蛋白激酶C三角酶 (PKCδ) 作为肝细胞癌 (HCC) 生物标志物的诊断效用.
- 评估PKCδ在检测各种患者亚组中HCC的性能,包括那些患有病毒性和非病毒性慢性肝病 (CLD) 的患者.
- 为了比较PKCδ与传统HCC标记物的有效性,考虑早期检测和混临床条件等因素.
主要方法:
- 分析了363名患有和没有HCC的慢性肝病 (CLD) 患者的血清样本.
- 使用三明治酶相关免疫吸收试验 (ELISA) 量化蛋白激酶C三角酶 (PKCδ) 水平.
- 评估了PKCδ的性能,以检测HCC的灵敏度和特异性,特别是在早期阶段和存在混因素时.
主要成果:
- 血清PKCδ在病毒和非病毒性CLD患者中显示出高灵敏度和特异性来检测HCC.
- PKCδ在识别非常早期的HCC时被证明是有效的.
- 关键的是,与传统标志物不同,PKCδ的性能不受C型肝炎病毒 (HCV) 消除状态,肝损伤或华法林的使用影响.
结论:
- 血清蛋白激酶C三角酶 (PKCδ) 是肝细胞癌 (HCC) 诊断的一个有希望和增强的生物标志物.
- PKCδ有效地弥补了与传统HCC标志物 (AFP和DCP) 相关的诊断局限性.
- 这些发现支持PKCδ作为提高HCC检测准确性和可靠性的宝贵工具,特别是在具有挑战性的临床场景中.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
5.2K
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
